Journal
FUTURE ONCOLOGY
Volume 18, Issue 27, Pages 2999-3009Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0596
Keywords
anagrelide; essential thrombocythemia; hydroxyurea; interferon; myeloproliferative neoplasm; P1101; pegylated interferon; ropeginterferon alfa-2b; SURPASS-ET
Categories
Ask authors/readers for more resources
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options. Hydroxyurea is the recommended treatment, but many patients experience resistance or intolerance. This article introduces interferon as a potential second-line therapy and mentions an ongoing clinical trial (SURPASS-ET) that will evaluate the efficacy and safety of a new type of interferon (ropeginterferon alfa-2b) compared to anagrelide.
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source. Hydroxyurea is the recommended treatment, but many patients experience resistance or intolerance. Anagrelide is an approved second-line option for ET, but concerns of a higher frequency of disease transformation may affect its role as a suitable long-term option. Interferons have been evaluated in myeloproliferative neoplasms for over 30 years, but early formulations had safety and tolerability issues. SURPASS-ET (NCT04285086) is a phase III, open-label, multicenter, global, randomized, active-controlled trial that will evaluate the safety, efficacy, tolerability and pharmacokinetics of ropeginterferon alfa-2b compared with anagrelide as second-line therapy in high-risk ET. Plain language summary: Essential thrombocythemia (ET) is a condition characterized by having more platelets than normal. The high number of platelets increases the risk of a life-threatening blood clot and/or bleeding. Patients with ET and at a high risk for these events are usually treated first with hydroxyurea (HU), but some patients do not respond properly or may develop significant side effects. Anagrelide is an approved medication used in patients who do not respond to HU. Ropeginterferon alfa-2b is a disease-specific, long-acting interferon with a good safety profile approved in polycythemia vera, another type of myeloproliferative neoplasm. The SURPASS-ET clinical trial will evaluate the safety, efficacy, tolerability and pharmacokinetics of ropeginterferon alfa-2b compared with anagrelide in patients with ET who are resistant or cannot tolerate HU. Tweetable abstract: New #OpenAccess phase III #clinical trial protocol comparing ropeginterferon alfa-2b to anagrelide for second-line treatment in ET and includes the history of #interferon use in myeloproliferative neoplasms
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available